NHS to reimburse Kaftrio triple therapy to treat cystic fibrosis. – Vertex.

Vertex Pharmaceuticals Incorporated announced that it has expanded its reimbursement agreement with NHS England for Vertex’s cystic fibrosis medicines to include Kaftrio (ivacaftor/tezacaftor/elexacaftor), in a combination regimen with Kalydeco (ivacaftor) 150 mg, ahead of the medicine’s anticipated approval by the European Commission.

The new expanded agreement includes reimbursed access to Vertex’s currently licensed medicines — Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor), as well as the triple combination therapy if approved — and any future additional licensed indications for all of these medicines.